Online ISSN: 2331-4737
www.oncoscience.us
About Oncoscience
Our mission is to cover the rapidly growing field of cancer research. We aim to focus on emergent topics not currently covered by other journals.
Oncoscience has also a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.

LEARN MORE ABOUT ONCOSCIENCE

Oncoscience | Association between tumor mutations and meningioma recurrence in Grade I/II disease

News

January 17, 2023
PRESS RELEASE: On December 9, 2022, a new research paper was published in Oncoscience, entitled, “Association between tumor mutations and meningioma recurrence in Grade I/II disease.” continue reading »

Oncoscience | Rapamycin in the context of Pascal’s Wager: generative pre-trained transformer perspective

News

December 27, 2022
PRESS RELEASE: On December 21, 2022, a new research perspective was published in Oncoscience, entitled, “Rapamycin in the context of Pascal’s Wager: generative pre-trained transformer perspective.” continue reading »

Behind the Study: Leveraging Scientific Findings to Develop Therapeutic Strategies for Dormant Breast Cancer Cells

Oncoscience

October 4, 2022
Alejandra Ferrer from the Department of Medicine-Hematology/Oncology at Rutgers New Jersey Medical School, describes a recent research perspective she co-authored that was published by Oncoscience, entitled, “Leveraging the scientific findings to develop therapeutic strategies for dormant breast cancer cells.” continue reading »

Oncoscience | As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression

Oncoscience

September 12, 2022
PRESS RELEASE: Dr. Blagosklonny published a new research commentary in Oncoscience, entitled, “As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression.” continue reading »